Hyperfine, Inc. (HYPR)
| Market Cap | 166.50M +175.6% |
| Revenue (ttm) | 13.56M +5.2% |
| Net Income | -35.57M |
| EPS | -0.43 |
| Shares Out | 98.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 354,183 |
| Open | 1.690 |
| Previous Close | 1.680 |
| Day's Range | 1.675 - 1.750 |
| 52-Week Range | 0.533 - 2.220 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 1.59 (-5.92%) |
| Earnings Date | May 12, 2026 |
About HYPR
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredi... [Read more]
Financial Performance
In 2025, Hyperfine's revenue was $13.56 million, an increase of 5.22% compared to the previous year's $12.89 million. Losses were -$35.57 million, -12.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for HYPR stock is "Strong Buy." The 12-month stock price target is $1.59, which is a decrease of -5.92% from the latest price.
News
Hyperfine, Inc. to Participate in Upcoming 2026 Jefferies Global Healthcare Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI syste...
Hyperfine announces AIIMS New Delhi initiated clinical use of Swoop
Hyperfine (HYPR) and the All India Institute of Medical Sciences, AIIMS, New Delhi announced that AIIMS New Delhi has initiated clinical use of the Swoop portable MRI system. “Bedside brain…
Hyperfine Swoop® System Introduced as India's First Portable MRI for Bedside Brain Imaging at the Country's Leading Medical Institution
NEW DELHI--(BUSINESS WIRE)--AIIMS New Delhi has begun clinical use of the Swoop® system, becoming the first hospital in India to deploy bedside MRI.
Hyperfine initiated with a Buy at BTIG
BTIG initiated coverage of Hyperfine (HYPR) with a Buy rating and $2 price target The company’s Swoop System enables point-of-care brain MRI at the bedside, expanding access to MRI imaging…
Hyperfine, Inc. to Announce First Quarter 2026 Financial Results on May 12, 2026
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine to report financial results for Q1 2026 on Tue., May 12, 2026. Management will host corresponding conference call at 1:30 PM PT/4:30 PM ET.
Hyperfine receives CE Marking, UK Conformity Assessment approval
Hyperfine (HYPR) announced it has received CE Marking and UK Conformity Assessment, UKCA, approval for both the next-generation Swoop system and the latest advancement in its Optive AI software. Toget...
Hyperfine Receives CE and UKCA Marks for Next-Generation Swoop® System and Latest Advancement in Optive AI™ Software
GUILFORD, Conn.--(BUSINESS WIRE)--Next-gen Swoop system and latest Optive AI software receive CE & UKCA marks, bringing Hyperfine's most advanced portable MRI tech to European markets.
Horizon Technology provides $40M loan facility to Hyperfine
Horizon Technology Finance Corporation (HRZN) has provided a $40M loan facility to Hyperfine (HYPR), with an initial funding of $15M at closing, and up to $25M available to support future…
Horizon Technology Finance Provides $40 Million Loan Facility to Hyperfine
FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $40 million loa...
Hyperfine price target raised to $1.60 from $1.30 at B. Riley
B. Riley raised the firm’s price target on Hyperfine (HYPR) to $1.60 from $1.30 and keeps a Buy rating on the shares. Hyperfine’s Q4 revenue was slightly above estimates, driven…
Hyperfine price target raised to $2.50 from $2 at Lake Street
Lake Street raised the firm’s price target on Hyperfine (HYPR) to $2.50 from $2 and keeps a Buy rating on the shares. Q4 “marked a step-function in system placements, and…
Hyperfine Earnings Call Transcript: Q4 2025
Q4 2025 revenue surged 128% year-over-year, driven by strong adoption of the next-gen Swoop system and Optive AI software, with robust growth in hospitals, neurology offices, and international markets. 2026 guidance projects 55% revenue growth and continued margin expansion.
Hyperfine reports Q4 EPS (6c) vs (14c) last year
Reports Q4 revenue $5.29M vs $2.32M last year. “The launch of our second-generation Swoop scanner, our Optive AI software, and the addition of a new market in the neurology office…
Hyperfine sees FY26 revenue $20M-$22M, one estimate $18M
Sees FY26 cash burn $26M-$28M.
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic ...
Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI syste...
Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System's Enhanced Stroke Detection Capabilities
GUILFORD, Conn.--(BUSINESS WIRE)--Strong evidence supports the use of AI-powered portable MRI for stroke detection in multiple clinical settings, including the emergency department.
Hyperfine announces results from NEURO PMR study
Hyperfine (HYPR) announced results from the NEURO PMR study, presented at the American Society of Neuroimaging annual meeting in San Juan, Puerto Rico on January 16. NEURO PMR is the…
Hyperfine Announces NEURO PMR Study Results Showing High Diagnostic Value and Superior Patient Experience in Neurology Clinics
GUILFORD, Conn.--(BUSINESS WIRE)--Results from the NEURO PMR study, presented by Dr. Laszlo Mechtler at the ASN Annual Meeting in San Juan, Puerto Rico, on January 16, 2026.
Hyperfine enrolls first patient in Contrast PMR study
Hyperfine (HYPR) announced the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center clinical study designed to evaluate the feasibility and visualization benefits of ...
Hyperfine Announces Enrollment of First Patient in Study to Expand Intended Use of the Swoop® System with Contrast Agents
GUILFORD, Conn.--(BUSINESS WIRE)--Prospective study is designed to evaluate the feasibility and visualization benefits of contrast-enhanced ultra-low-field portable MRI.
Hyperfine reports preliminary Q4 revenue $5.3M, consensus $5M
Reports preliminary FY25 revenue $13.5M, consensus $13.3M. “I am very pleased with our record fourth quarter, driven by success across all business verticals with placements in hospitals including tec...
Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI syste...
Hyperfine Announces First Peer-Reviewed Publication Demonstrating Significant Economic Benefits of Using the Swoop® AI-Powered Portable MRI System in Acute Hospital Care
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces the first analysis showing the AI-powered Swoop® portable MRI system reduces hospital costs and improves economics in acute care.
Hyperfine announces regulatory approval of Swoop System in India
Hyperfine (HYPR) announced the Swoop system has received regulatory approval in India from the Central Drugs Standard Control Organization.